Source: Contract Pharma

Adgero: DelMar Pharma to Acquire Adgero Biopharma

Merger combines DelMar's DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero's photodynamic therapy platform.

Read full article »
Adgero's Competitors | Adgero's News | Adgero's Financials
Stay up-to-date with the latest news on Adgero Biopharmaceuticals Holdings, Inc.
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
CEO Avatar

Interim-CEO

John Liatos

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Adgero Biopharmaceuticals Holdings, Inc.